TrialThe Journal of investigative dermatology2022

Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: A Randomized Clinical Trial.

Victoria P Werth et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.